353 related articles for article (PubMed ID: 14673039)
21. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Papadimitriou CA; Papakostas P; Timotheadou E; Aravantinos G; Bamias A; Fountzilas G
Cancer Invest; 2008 Jun; 26(5):491-8. PubMed ID: 18568771
[TBL] [Abstract][Full Text] [Related]
23. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
[TBL] [Abstract][Full Text] [Related]
24. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
25. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
[TBL] [Abstract][Full Text] [Related]
26. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
27. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
[TBL] [Abstract][Full Text] [Related]
29. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Tzaida O; Gogas H; Dafni U; Kyroudi A; Papaspyrou I; Kyriakou V; Malamou-Mitsi V; Alamani M; Skopa C; Kostopoulos I; Kastritis E; Pectasides D; Briasoulis E; Kalofonos HP; Aravantinos G; Fountzilas G; Arapantoni-Dadioti P
Oncology; 2007; 72(5-6):388-96. PubMed ID: 18187961
[TBL] [Abstract][Full Text] [Related]
31. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Burstein HJ; Bellon JR; Galper S; Lu HM; Kuter I; Taghian AG; Wong J; Gelman R; Bunnell CA; Parker LM; Garber JE; Winer EP; Harris JR; Powell SN
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):496-504. PubMed ID: 16243442
[TBL] [Abstract][Full Text] [Related]
32. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
33. Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).
Kahán Z; Spanik S; Wagnerova M; Skacel T; Planko B; Fitzthum E; Lindner E; Soldatenkova V; Zielinski CC; Brodowicz T
Breast Cancer Res Treat; 2008 Dec; 112(3):557-63. PubMed ID: 18189160
[TBL] [Abstract][Full Text] [Related]
34. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
[TBL] [Abstract][Full Text] [Related]
35. Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer.
Bos AM; de Graaf H; de Vries EG; Piersma H; Willemse PH
Br J Cancer; 2000 Jun; 82(12):1920-4. PubMed ID: 10864198
[TBL] [Abstract][Full Text] [Related]
36. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.
Griggs JJ; Culakova E; Sorbero ME; Poniewierski MS; Wolff DA; Crawford J; Dale DC; Lyman GH
J Clin Oncol; 2007 Jun; 25(18):2522-7. PubMed ID: 17577029
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
38. Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer.
Ladwa R; Kalas T; Pathmanathan S; Woodward N; Wyld D; Sanmugarajah J
Clin Breast Cancer; 2018 Oct; 18(5):e1181-e1187. PubMed ID: 29778788
[TBL] [Abstract][Full Text] [Related]
39. Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens.
Genre D; Viens P; Bertucci F; Chabannon C; Gravis G; Braud AC; Camerlo J; Houvenaeghel G; Moutardier V; Goncalvez A; Protière C; Bardou VJ; Maraninchi D
Bone Marrow Transplant; 2002 Jun; 29(11):881-6. PubMed ID: 12080351
[TBL] [Abstract][Full Text] [Related]
40. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
Paré L; Altés A; Ramón y Cajal T; Del Rio E; Alonso C; Sedano L; Barnadas A; Baiget M
Anticancer Drugs; 2007 Aug; 18(7):821-5. PubMed ID: 17581305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
